Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
09/2003
09/11/2003US20030171334 Treatment of prostate cancer
09/11/2003US20030171331 Oxazolidinone cotherapy
09/11/2003US20030171324 Reagents which bind to human DESC1-like serine protease gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to cancer, chronic obstructive pulmonary disease (COPD),
09/11/2003US20030171320 Methods for treating ocular neovascular diseases
09/11/2003US20030171317 Methods and compositions for reducing bacterial tolerance to antibacterials, disinfectants and organic solvents
09/11/2003US20030171306 Cancer treatment method
09/11/2003US20030171299 Stable, biologically compatible pharmaceutical compositions in the form of water-in-oil microemulsions (w/o), for the sustained release by parenteral administration of active ingredients which are hydrophilic or are made hydrophilic by
09/11/2003US20030171294 Unit angiogenic agent, typically from 5 ng to 67,500 ng. Preferably, the angiogenic agent is FGF, more preferably it is basic FGF, Inducing angiogenesis or myocardial perfusion or vascular density into a heart
09/11/2003US20030171291 Novel treatment
09/11/2003US20030171288 Methods for the prevention and treatment of a variety of mammalian conditions manifested by loss of bone mass, including osteoporosis. The present invention provides methods of using PTHrP, or analogs thereof, for the treatment of
09/11/2003US20030171271 Therapeutic application in the treatment of conditions including cancer, macular degeneration and retinopathies. Also included are methods of treating a patient having a pathological condition characterized by an increase in
09/11/2003US20030171263 Methods for treating transplant rejection
09/11/2003US20030171255 Modulating the phosphorylation of DARPP-32 in a serotonergic receptor intracellular signaling pathway. The invention provides methods and compositions for modulating the activities of DARPP-32, casein kinase 1 (CK1),
09/11/2003US20030170891 RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
09/11/2003US20030170866 Novel cyclin-selective ubiquitin carrier polypeptides
09/11/2003US20030170859 Gene expression inhibition; for treatment of inflammatory, neurological, cardiovascular, and neoplastic tisssue growth disorders
09/11/2003US20030170839 Type 2 cytokine receptor and nucleic acids encoding same
09/11/2003US20030170812 Interleukin-1beta converting enzyme like cysteine protease
09/11/2003US20030170808 Polypeptide encoded by polynucleotide of given sequence; use in diagnosis and treatment of various diseases
09/11/2003US20030170792 MAGE-3 peptides presented by HLA class ll molecules
09/11/2003US20030170785 CDNA encoding the human alpha2 delta4 calcium channel subunit
09/11/2003US20030170746 Method for screening an agent for ability to inhibit heparanase activity
09/11/2003US20030170730 Testing for drug desistance of cancer drugs
09/11/2003US20030170651 Method of identifying a polymorphism in CYP2D6
09/11/2003US20030170648 Autoimmune diseases; inflammatory bowel disease; multiple sclerosis; rheumatic diseases; modulate gene expression
09/11/2003US20030170628 Forsenic analysis; medical diagnosis; chromosome markers
09/11/2003US20030170334 Use of Emu Oil and its various fractions as a carrier for antifungal, antibacterial, and antiviral medications & preparations
09/11/2003US20030170324 Microencapsulated oil
09/11/2003US20030170322 Throat care agents
09/11/2003US20030170319 Nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer
09/11/2003US20030170318 Treating cancer by administering a fluoride or a salt thereof; e.g., sodium fluoride, calcium fluoride, magnesium fluoride, potassium fluoride, aluminum fluoride, strontium fluoride or sodium monofluorophosphate.
09/11/2003US20030170316 Treating asthma by preventing and/or accomodating for S-nitrosothiol breakdown
09/11/2003US20030170303 That has low water solubility such as celecoxib; and a release- extending polymer.
09/11/2003US20030170300 Combination chemotherapy
09/11/2003US20030170299 Therapeutic methods for acute myeloid leukemia
09/11/2003US20030170295 Hydrogel composition for transdermal drug delivery
09/11/2003US20030170289 Injectable depot compositions and uses thereof
09/11/2003US20030170288 Drug delivery composition
09/11/2003US20030170287 Rapamycin or a rapamycin derivative having mTOR inhibiting properties
09/11/2003US20030170286 Codrug with at least two constituent moieties cleavably linked covalently to one another; dimensioned to position two radiation seeds a predetermined distance apart.
09/11/2003US20030170273 Type 1 interferon inducers, such as double-stranded RNA, in combination with antigen delivery systems and/or immunostimulatory molecules for enhancing the immune response of a coadministered antigen
09/11/2003US20030170258 Transmucosally administering an epitope which is located in close proximity to said immune response, wherein said modulation comprises induction of oral tolerization to said antigen.
09/11/2003US20030170235 Treatment with anti-ErbB2 antibodies
09/11/2003US20030170234 Combination of the antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin; treating cancer
09/11/2003US20030170223 Pulmonary vasodilator surfactant compositions and method of use
09/11/2003US20030170199 For care and prevention of the signs of ageing of the skin
09/11/2003US20030170181 Method for preventing abuse of methylphenidate
09/11/2003US20030167999 Crystal
09/10/2003EP1343013A1 Methods of screening apoptosis modulating compounds, compounds identified by said methods and use of said compounds as therapeutic agents.
09/10/2003EP1342729A2 Antibodies and antisense molecules for G-coupled receptor showing selective affinity for ATP
09/10/2003EP1342489A1 Method of affecting sleep and sleep-related behaviors
09/10/2003EP1342476A2 FGFR3 as a marker for mesenchymal skeletal progenitor cells and use of cytotoxic conjugates comprising an FGFR3 binding agent for the treatment of cartilagineous bony tumours
09/10/2003EP1342475A1 Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
09/10/2003EP1342410A2 Transgenic animals lacking a functional galanin gene
09/10/2003EP1341923A2 Methods for enhancing the efficacy of cancer therapy
09/10/2003EP1341921A2 Hydrolases
09/10/2003EP1341918A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
09/10/2003EP1341905A2 Tec kinase assay
09/10/2003EP1341818A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
09/10/2003EP1341782A2 Inhibitors of p38 kinase
09/10/2003EP1341777A2 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl)piperazine and pharmaceutically acceptable salts and solvates thereof and their use in the treatement of incontinence
09/10/2003EP1341773A2 Substituted 1,3,5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis
09/10/2003EP1341771A2 Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
09/10/2003EP1341769A2 Bacterial gyrase inhibitors and uses thereof
09/10/2003EP1341767A2 Imidazole and benzimidazole caspase inhibitors and uses thereof
09/10/2003EP1341764A1 Ortho-substituted nitrogen-containing bisaryl compounds used as potassium channel inhibitors
09/10/2003EP1341565A2 Drug delivery compositions and coated medical devices
09/10/2003EP1341553A1 Silensed anti-cd28 antibodies and use thereof
09/10/2003EP1341551A2 Treatment of posterior capsule opacification
09/10/2003EP1341549A2 Combination therapy for estrogen-dependent disorders
09/10/2003EP1341543A2 Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
09/10/2003EP1341541A1 Combination therapy for lowering and controlling intraocular pressure
09/10/2003EP1341540A2 Tyrosine kinase inhibitors
09/10/2003EP1341538A2 Novel medicament compositions
09/10/2003EP1341537A2 Pharmaceutically active isoindoline derivatives
09/10/2003EP1341536A2 Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
09/10/2003EP1341533A1 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
09/10/2003EP1341529A2 Hydrolytically unstable compositions
09/10/2003EP1341528A1 Rapidly disintegrating tablet comprising an acid-labile active ingredient
09/10/2003EP1341527A1 Pharmaceutical preparation comprising an active dispersed on a matrix
09/10/2003EP1341520A2 Antibiotic/benzoyl peroxide dispenser
09/10/2003EP1341515A1 Water-free skin care formulations comprising micronized urea and method of manufacturing the same
09/10/2003EP1341497A2 Receptor antagonist-lipid conjugates and delivery vehicles containing same
09/10/2003EP1341476A2 Intrasvascular drug delivery device and use therefor
09/10/2003EP1296948B1 Novel gamma crystalline form of perindopril tert-butylamine salt, preparation method, and pharmaceutical compositions containing same.
09/10/2003EP1248601B1 Control of microbial populations in the gastrointestinal tract of animals
09/10/2003EP1165136B1 Combination therapy of angiotensin converting enzyme inhibitor and epoxy-steroidal aldosterone antagonist for treatment of cardiovascular disease
09/10/2003EP1124572B1 Genes and proteins predictive and therapeutic for renal disease and associated disorders
09/10/2003EP1035835B1 Long acting injectable formulations containing hydrogenated castor oil
09/10/2003EP0981377B1 cOMPLEXES OF THE LHRH-ANTAGONIST CETRORELIX WITH POLY-AMINO ACIDS AND METHOD FOR THEIR PRODUCTION
09/10/2003EP0906122B1 Activated linkers and methods for making and purifying the same
09/10/2003EP0772396B1 Method of regulating immune function
09/10/2003EP0737067B1 Treatment of hormone-unresponsive metastatic prostate cancer
09/10/2003CN1441841A Stimulation of cellular regeneration and differentiation in inner ear
09/10/2003CN1441810A Soluble CTL A4 mutant molecules and use thereof
09/10/2003CN1441808A Chemokine receptor modulators, production and use
09/10/2003CN1441806A Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising N-cyclic P2 moieties
09/10/2003CN1441785A Tetrahydroixoquinoline analogs useful as growth hormone secretagogues
09/10/2003CN1441780A Piperidine compounds for use as CCR-3 inhibitors
09/10/2003CN1441775A Hiv整合酶抑制剂 Hiv integrase inhibitors
1 ... 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 ... 1151